Skip to Main Content

Paper Details

A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia.
Leuk Lymphoma
3
2022

Datasets

Release 1.2